EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
29/10/2025
Voltar para busca
Dado oficial do USPTO
ILLUMINA COVIDSEQ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ILLUMINA COVIDSEQ
ST13
US500000088983897Classe
1, 5
Pedido
88983897
Registro
6913584
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
05/11/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
29/04/2020
Data de registro
29/11/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/11/2022
Última transação
05/11/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
14/05/2020
Primeiro uso no comércio
09/06/2020
Código do desenho
4
Tipo de titular
03
Localização do titular
San Diego, CA
Examinador
HUSSAIN,TASNEEM
Unidade examinadora
M90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Illumina, Inc.
Representantes
Susan M. Natland Baker & Hostetler LLP
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Agentsreagentsassaysenzymesnucleotidesbufferschemical preparationsbiological preparations for scientific and research use; Diagnostic reagents and preparationsother than for medical or veterinary use; Kits comprised principally of reagents with a protocol for use thereof for non-medical purposes; Agentsreagentsassaysenzymesnucleotidesbufferschemical preparationsbiological preparations for scientific and research use in the fields of nucleic acid sequencinggenotypingdiagnosticsdiagnostic researchclinical researchdrug developmentpharmaceuticalslaboratory researchscientific researchmedical researchlife sciencesbiologymicrobiology and metagenomicsbiotechnologyagricultureforensicsfood safetygenetic testinggeneticsnot for medical or veterinary purposes; Kits comprising nucleotidesreagentsenzymesagentsassaysbufferschemical preparationsbiological preparations for scientific and research use including in the fields of nucleic acid sequencinggenotypingdiagnosticsdiagnostic researchclinical researchdrug developmentpharmaceuticalslaboratory researchscientific researchmedical researchlife sciencesbiologymicrobiology and metagenomicsbiotechnologyagricultureforensicsfood safetygenetic testinggeneticsnot for medical or veterinary purposes; all of the foregoing for the detection of or in the field of COVID-19
Classe 5
Agentsreagentsassaysenzymesnucleotidesbufferschemical preparationsbiological preparations for scientific and research use; Diagnostic reagents and preparationsother than for medical or veterinary use; Kits comprised principally of reagents with a protocol for use thereof for non-medical purposes; Agentsreagentsassaysenzymesnucleotidesbufferschemical preparationsbiological preparations for scientific and research use in the fields of nucleic acid sequencinggenotypingdiagnosticsdiagnostic researchclinical researchdrug developmentpharmaceuticalslaboratory researchscientific researchmedical researchlife sciencesbiologymicrobiology and metagenomicsbiotechnologygenetic testinggeneticsnot for medical or veterinary purposes; Kits comprising nucleotidesreagentsenzymesagentsassaysbufferschemical preparationsbiological preparations for scientific and research use including in the fields of nucleic acid sequencinggenotypingdiagnosticsdiagnostic researchclinical researchdrug developmentpharmaceuticalslaboratory researchscientific researchmedical researchlife sciencesbiologymicrobiology and metagenomicsbiotechnologygenetic testinggeneticsnot for medical or veterinary purposes; all of the foregoing for the detection of or in the field of COVID-19
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/10/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/10/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/10/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/10/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
29/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
29/11/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
28/10/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
27/10/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
21/10/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
20/10/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
19/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/10/2022
ALIE
ASSIGNED TO LIE
17/10/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/09/2022
EEXT
SOU TEAS EXTENSION RECEIVED
20/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/03/2022
GNRT
NON-FINAL ACTION E-MAILED
08/03/2022
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/03/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/03/2022
DPCC
DIVISIONAL PROCESSING COMPLETE
03/03/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/03/2022
IUAF
USE AMENDMENT FILED
16/02/2022
DRRR
DIVISIONAL REQUEST RECEIVED
16/02/2022
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
16/02/2022
EISU
TEAS STATEMENT OF USE RECEIVED
16/02/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/02/2022
EX1G
SOU EXTENSION 1 GRANTED
01/02/2022
EXT1
SOU EXTENSION 1 FILED
01/02/2022
EEXT
SOU TEAS EXTENSION RECEIVED
01/02/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/08/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/06/2021
PUBO
PUBLISHED FOR OPPOSITION
08/06/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/05/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/05/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
30/04/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/04/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
30/04/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/04/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/04/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/10/2020
GNRT
NON-FINAL ACTION E-MAILED
21/10/2020
CNRT
NON-FINAL ACTION WRITTEN
21/10/2020
DOCK
ASSIGNED TO EXAMINER
19/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/05/2020
NWAP
NEW APPLICATION ENTERED
02/05/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ILLUMINA COVIDSEQ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.